Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

Ines Pires Da Silva, Tasnia Ahmed, Jennifer L. McQuade, Caroline A. Nebhan, John J. Park, Judith M. Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K. Oberoi, Selma Ugurel, Lauren E. Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pfohler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat RaiJessica L. Smith, Richard A. Scolyer, Ana M. Arance, Lisa Pickering, James Larkin, Paul Lorigan, Christian U. Blank, Dirk Schadendorf, Michael A. Davies, Matteo S. Carlino, Douglas B. Johnson, Georgina V. Long, Serigne N. Lo, Alexander M. Menzies

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences